北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 眼科  > 期刊论文
学科主题: 临床医学
题名:
Bevacizumab for Neovascular Age-related Macular Degeneration in China
作者: Li, Xiaoxin1,2; Hu, Yonghua4; Sun, Xiaodong3; Zhang, Junjun5; Zhang, Maonian6; Neovasc Age-Related Macular Degene1
刊名: OPHTHALMOLOGY
发表日期: 2012-10-01
DOI: 10.1016/j.ophtha.2012.05.016
卷: 119, 期:10, 页:2087-2093
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Ophthalmology
研究领域[WOS]: Ophthalmology
关键词[WOS]: POLYPOIDAL CHOROIDAL VASCULOPATHY ; INTRAVITREAL INJECTION ; AVASTIN THERAPY ; RANIBIZUMAB ; PHARMACOKINETICS ; SAFETY
英文摘要:

Objective: To evaluate 2 different dosing regimens of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) patients in China.

Design: Multicenter, randomized, prospective, open-label clinical trial.

Participants: One hundred eighty-five patients with active neovascular AMD, exclusion of a macular scar, choroidal neovascularization not resulting from AMD, and polypoidal choroidal vasculopathy.

Intervention: Patients were assigned randomly to receive intravitreal injections of bevacizumab every 6 weeks for the first 3 injections followed by injections every 6 weeks (regimen A, n = 91) or every 12 weeks (regimen B, n = 94).

Main Outcome Measures: The primary outcome measure was a comparison of the mean change in visual acuity from baseline. The secondary outcome measure was a comparison of the proportion of patients with a change in visual acuity of 15 letters or more. Adverse events were monitored.

Results: One-hundred eighty five patients were enrolled. At 48 weeks, the increase in the mean visual acuity measurements from baseline were 12.58 letters in regimen A and 10.06 letters in regimen B (P = 0.288). At 48 weeks, the percentage of eyes losing fewer than 15 letters was 96.2% in regimen A and 93.9% in regimen B (P = 0.720). At 48 weeks, the median decrease in central retinal thickness measurements from baseline was 119 mu m in regimen A and 60 mu m in regimen B (P = 0.221). Adverse events during the 48 weeks included anterior chamber inflammation in 17 patients (18.7%) from regimen A and 9 patients (9.6%) from regimen B (P = 0.075). There were no other notable ocular adverse events in either group.

Conclusions: Intravitreal bevacizumab improved visual acuity and decreased macular thickness in patients with neovascular AMD when dosed either every 6 weeks or every 12 weeks after 3 doses given at 6-week intervals. Although there were no statistically significant differences between the 2 regimens, the results tended to favor the group dosed every 6 weeks (regimen A).

语种: 英语
所属项目编号: 2006BAI02B05
项目资助者: National Key Technology Research and Development Program in the 11th Five-Year Plan of China
WOS记录号: WOS:000310581900023
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51511
Appears in Collections:北京大学第二临床医学院_眼科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China
2.PLA, Dept Ophthalmol, Gen Hosp, Beijing, Peoples R China
3.Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China
4.Shanghai Jiao Tong Univ, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China
5.Peking Univ, Sch Publ Hlth, Beijing 100044, Peoples R China
6.Sichuan Univ, Dept Ophthalmol, W China Hosp, Chengdu 610064, Peoples R China

Recommended Citation:
Li, Xiaoxin,Hu, Yonghua,Sun, Xiaodong,et al. Bevacizumab for Neovascular Age-related Macular Degeneration in China[J]. OPHTHALMOLOGY,2012,119(10):2087-2093.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Xiaoxin]'s Articles
[Hu, Yonghua]'s Articles
[Sun, Xiaodong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Xiaoxin]‘s Articles
[Hu, Yonghua]‘s Articles
[Sun, Xiaodong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace